Media Thread, page-10791

Hi Sorest!

Yep - I agree. Nothing wrong with competition. It's unlikely that any single allogeneic CAR-T will suit every condition and every patient. The more choice people have, the better. There are something like 6 autologous CAR-T's in the market.

I hope Celularity does continue with Cycart-19, as a standalone and in combo with OnCARlytics. That wouldn't hurt Imugene really. Assuming OnCARlytics works as well in humans as it did in preclinical studies - and we are starting to get hints that it does - then more partner drugs for combination with it can only help OnCARlytics to be an easier and more obvious choice for clinicians to make.

Regulatory approvals will develop in a patchwork fashion - initially for one specific indication. Then another. Then another. If Celularity identifies a target indication for OnCARlytics + Cycart-19, and pursues that successfully, then they get a win but so Does Imugene, and at minimal cost to IMU.

The same will be true for the IMU partnership with Eureka Therapeutics and their Artemis CD19 targeting CAR-T.

Bring it on!

Interesting times ahead, and hopefully success for all - especially patients.

Cheers

Dave